These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. European Animal Tissue Directive. Donawa M Med Device Technol; 2004; 15(1):28-31. PubMed ID: 14994636 [TBL] [Abstract][Full Text] [Related]
3. Engineering human tissue and regulation: confronting biology and law to bridge the gaps. Longley D; Lawford P Med Law Int; 2001; 5(2):101-15. PubMed ID: 14696620 [TBL] [Abstract][Full Text] [Related]
4. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle]. Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926 [TBL] [Abstract][Full Text] [Related]
5. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products. Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714 [TBL] [Abstract][Full Text] [Related]
6. Engineered tissues: the regulatory path from concept to market. Hellman KB Adv Exp Med Biol; 2006; 585():363-76. PubMed ID: 17120795 [No Abstract] [Full Text] [Related]
8. What is the QSR/GMP, and why should you care? Bartoo G IEEE Eng Med Biol Mag; 2004; 23(2):98-9. PubMed ID: 15264479 [No Abstract] [Full Text] [Related]
9. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics. Lodén M; Ungerth L; Serup J Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885 [TBL] [Abstract][Full Text] [Related]
10. What is in the QSR/GMP? Bartoo G; IEEE Eng Med Biol Mag; 2004; 23(4):83-5. PubMed ID: 15508391 [No Abstract] [Full Text] [Related]
11. CAT--the new committee for advanced therapies at the European Medicines Agency. Celis P Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354 [TBL] [Abstract][Full Text] [Related]
12. A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing. Klarmann D; Sireis W; Hogardt M; Kempf VA; Seifried E; Bonig H Cell Tissue Bank; 2015 Sep; 16(3):311-8. PubMed ID: 25204399 [TBL] [Abstract][Full Text] [Related]
13. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products. Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099 [TBL] [Abstract][Full Text] [Related]
15. Regulation of Regenerative Medicine Products. Gee AP Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372 [TBL] [Abstract][Full Text] [Related]
16. US and European postmarket clinical data requirements. Donawa M Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495 [TBL] [Abstract][Full Text] [Related]
18. Current issues in the regulation of human tissue-engineering products in the European Union. Heinonen M; Oila O; Nordström K Tissue Eng; 2005; 11(11-12):1905-11. PubMed ID: 16411837 [TBL] [Abstract][Full Text] [Related]
19. EU and US clinical investigation adverse event reporting. Crowley G Med Device Technol; 2004 Jun; 15(5):30-2. PubMed ID: 15285486 [TBL] [Abstract][Full Text] [Related]
20. Making 'safety first' a reality for biotechnology products. Kapuscinski AR; Goodman RM; Hann SD; Jacobs LR; Pullins EE; Johnson CS; Kinsey JD; Krall RL; La Viña AG; Mellon MG; Ruttan VW Nat Biotechnol; 2003 Jun; 21(6):599-601. PubMed ID: 12776139 [No Abstract] [Full Text] [Related] [Next] [New Search]